Abstract
Aim: This study focused on the effects of recombinant human brain natriuretic peptide combined with levosimendan on the efficacy and Interleukin- 6, Tumor Necrosis Factor-α, D-Dimer of patients with heart failure.
Methods: This study included 162 patients who were treated for heart failure from March 2022 to March 2024 in our hospital. Randomly divided into three groups, all three groups were given conventional treatment plus nutritional therapy, one group was given recombinant human brain natriuretic peptide treatment on this basis, the second group was given levosimendan treatment on this basis, the third group was given recombinant human brain natriuretic peptide and levosimendan combination treatment. The treatment efficacy, cardiac function, renal function, inflammatory factors, nutritional status and quality of life of patients in the three groups were compared.
Results: The results indicated that all three groups could improve the patients' efficacy, cardiac and renal function and nutritional status, inhibited the development of inflammatory factors and improved the quality of life, with the most significant improvement in combination group. IL-6 and TNF-α were notably lower than before and tended to be in the normal range after treatment in the three groups. The effect of TG on inflammation was the most notable(P < 0.05), ALB, TP, HGB and MNA levels were notably higher after treatment than before treatment in all groups (P < 0.05).
Conclusion: IN conclusion, recombinant human brain natriuretic peptide combined with levosimendan treatment based on nutritional support can effectively improve the efficacy, nutritional status and quality of life of patients with heart failure.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.